Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve, Inc. is a Canada-based healthcare technology company. The Company has two business units: Medivolve Pharmacy Division (MPD) and Collection Sites Diagnostics (CSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine, and psychiatry to patients in Southern California. CSD’s software platform, Electronic Health Records app (EHR), is focused on supporting clinical staff, is a series of assets and functionalities that enhance the customer experience and provide an end-to-end lab solution. The Company, through its subsidiaries, Medivolve Pharmacy Inc., and Kedy Ying Jao D.O., a medical corporation, operate a distributed network of two retail patient-care locations in California, United States. The Company has served hundreds of thousands of patients across the United States and facilitated more than 1,533,000 clinical tests.


OTCPK:MEDVF - Post by User

Post by Hiddensecretson Nov 23, 2020 9:15pm
785 Views
Post# 31957980

Q3 Earnings Report - Sept 30th: Min. $ 3 million in sales

Q3 Earnings Report - Sept 30th: Min. $ 3 million in salesQ3 Earnings report should be released by November 30, 2020 or next week. 

I am expecting at the low end $ 3 million in sales, top end maybe $ 4 million.

This revenue comes from Columbia having sold 750,000 covid19 kits at $ 4 each, funds were used to pay down loan of $ 7.7 million.   There were other launches during the quarter but I ignore home much they brought in. 

For Q4 - October to December 2020, should show ROBUST revenue, how much is anyone's guess, but we will have 415 units on December 31, 2020, each with strong demand, so do the math.

And for Q1 - January to March 2021, it will be BLOCKBUSTER revenue as we are going to shoot up towards the 2,000 units testing center.

And for Q2 - April to June 2021, demand will be ferocious as we may be doing vaccine, antibody and antigen....

Covid19 will be here for a long time as it is out of control around the world.   Even if they vaccinate 1 billion people in 2021, there are still close to another 7 billion that need vaccinations.   It will takes year.

Quescap said normal may return in the middle of this decade meaning 2025 and not earlier. 

MPO
<< Previous
Bullboard Posts
Next >>